MAP2K6 and atrial fibrillation: In vivo, utilizing an AF puncture-induced IDD rat model, we validated that inactivating MAP2K6 by Omilancor treatment aids in avoiding the reduction of IVDs height, loss of NP water content, loss of NP cells and degradation of ECM caused by AF puncture.